Anthem Biosciences Limited , a prominent player in the Contract Research, Development and Manufacturing Organization (CRDMO) and Speciality Ingredients sectors, has announced its financial results for the second quarter of fiscal year 2026, ending September 30, 2025.

Financial Highlights

The company reported a consolidated total income of Rs. 5,982.56 crore for Q2 FY2026, marking a 8.2% increase from Rs. 5,528.01 crore in the same quarter last year. However, profit before tax (PBT) saw an increase to Rs. 2,296.03 crore from Rs. 1,995.33 crore year-over-year, representing a 15.1% growth.

For a clearer picture of the company's performance, here's a breakdown of the key financial metrics:

Segment Performance

Anthem Biosciences operates through two main segments:

1. CRDMO (Contract Research, Development and Manufacturing Organization): This segment generated revenue of Rs. 4,658.13 crore in Q2 FY2026.
2. Speciality Ingredients: This segment contributed Rs. 842.14 crore to the quarterly revenue.

Half-Year Performance

For the half-year ended September 30, 2025, Anthem Biosciences reported:

• Total income of Rs. 11,612.77 crore, up from Rs. 9,108.50 crore in the previous year.
• Profit before tax increased to Rs. 4,158.51 crore from Rs. 3,175.09 crore year-over-year.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

• Total assets of Rs. 32,842.97 crore
• Total equity of Rs. 27,525.45 crore
• Cash and cash equivalents of Rs. 5,038.31 crore

Management Commentary

The Board of Directors approved these results in their meeting held on November 8, 2025. The company's equity shares have been listed on the National Stock Exchange of India Limited (NSE) and BSE Limited since July 21, 2025, following its Initial Public Offering (IPO).

Conclusion

Anthem Biosciences has shown growth in both revenue and profit for the quarter. The company's strong performance in the CRDMO segment and its recent listing on major stock exchanges position it as a notable player in the biosciences industry. The consistent growth in total income and profit before tax, both for the quarter and half-year, indicates positive momentum for the company.

Anthem Biosciences Limited has disclosed a violation of its Code of Conduct by a designated person, as per a recent regulatory filing. The company reported that the individual in question traded in company securities during a trading window closure period, contravening the SEBI Prohibition of Insider Trading Regulations.

Details of the Violation

The company has provided the following information regarding the incident:

Company's Response

Anthem Biosciences has stated that the matter will be tabled at the forthcoming Audit Committee meeting. The company has committed to providing a detailed disclosure and information about the action taken in due course.

Regulatory Compliance

The disclosure was made in compliance with Regulation 9(1) of the SEBI PIT Regulations and the company's internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons.

Implications

This incident highlights the importance of adherence to insider trading regulations and company policies. It also underscores the need for designated persons within companies to be vigilant about trading window restrictions to maintain market integrity and investor confidence.

Anthem Biosciences has assured that it will provide further details and information about the actions taken in response to this violation, in accordance with SEBI Master Circular No. SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/039 dated March 23, 2023.

Investors and market participants may be watching for the outcome of the Audit Committee meeting and the subsequent actions taken by the company in response to this regulatory breach.